Atlas Four · Vaccine · mRNA

mRNA-1273 (Spikevax)

Moderna/NIH modified-nucleoside mRNA-LNP COVID-19 vaccine — sequence-to-IND in 42 days, proof of the platform hypothesis that had been built over 15 years.

SM-102 LNP · 100 µg dose · 94.1% efficacy (COVE) · FDA EUA Dec 18, 2020 · WHO EML listed

94.1%COVE Efficacy
42 daysSequence to IND
100 µgAdult Dose
2PPrefusion-Stabilized Spike
Vaccine Atlas · mRNA · Lipid Nanoparticle

mRNA-1273 (Spikevax)

Platform: Modified-nucleoside mRNA / SM-102 LNP  |  Route: Intramuscular  |  Developer: Moderna, Inc. & NIAID Vaccine Research Center

Modified-nucleoside mRNA (N1-methylpseudouridine) encoding the SARS-CoV-2 prefusion-stabilized spike (2P mutations K986P/V987P), encapsulated in a four-lipid SM-102 LNP. SARS-CoV-2 genome sequence finalized January 10–11, 2020; mRNA-1273 sequence finalized January 13; first clinical vial shipped February 24; first human dose March 16. This was not designed in 6 weeks — it was assembled in 6 weeks from 15 years of convergent platform science. Phase 3 COVE trial: 94.1% efficacy.

Spikevax elasomeran CX-024414 Moderna COVID-19 vaccine

Overview

mRNA-1273 was co-developed by Moderna, Inc. (Cambridge, Massachusetts) and the NIH Vaccine Research Center (NIAID/VRC) under Barney Graham, Kizzmekia Corbett, and Jason McLellan. The vaccine is the most consequential demonstration that a pathogen genome can be translated into a protective vaccine candidate in weeks — a proof of concept that the field had pursued for a decade using respiratory syncytial virus (RSV F) and MERS-CoV spike as model antigens.

Three independent technology streams converged: modified-nucleoside mRNA chemistry (Katalín Karikó and Drew Weissman, 2005 onward — replacing uridine with N1-methylpseudouridine to evade TLR7/TLR8 and dramatically boost translation); prefusion-stabilized class-I fusion glycoproteins (Graham/McLellan/Corbett, 2013–2017 — two proline substitutions lock the spike in immunogenic prefusion conformation); and lipid nanoparticle delivery (Pieter Cullis / Acuitas / Arbutus IP lineage — ionizable lipid particles for cytoplasmic mRNA delivery). mRNA-1273 was not designed in 6 weeks. It was assembled in 6 weeks; the design took 15 years.

FDA Emergency Use Authorization came on December 18, 2020. Phase 3 COVE trial (NCT04470427; 30,420 participants) reported 94.1% efficacy (95% CI 89.3–96.8%) against symptomatic COVID-19. Full approval as Spikevax for adults came January 31, 2022; pediatric full approval July 10, 2024. mRNA-1273 is on the WHO Essential Medicines List — the only mRNA vaccine to achieve that designation.

Platform & Antigen Design

mRNA Construct and SM-102 LNP

  mRNA-1273 construct (~4,200 nt, N1-methylpseudouridine throughout):
    5' cap1 (m7G) → 5' UTR (β-globin based) → [spike CDS] → 3' UTR (β-globin) → poly(A) ~100 nt

  Spike: full-length SARS-CoV-2 S with K986P + V987P (2P stabilization)
    ┌─ Proline kinks lock central helix in prefusion bundle
    └─ RBD-up state preserved → optimal neutralizing epitope display (PDB 6VSB)

  SM-102 LNP (four-lipid, ~80-100 nm):
    SM-102     (~50%)  ionizable lipid — neutral at pH 7.4; protonated in endosome → disrupts membrane
    DSPC       (~10%)  structural phospholipid
    Cholesterol(~38.5%) membrane fluidity modulator
    PEG2000-DMG(~1.5%) surface PEGylation — prevents aggregation; sheds within hours

  IM injection (deltoid, 100 µg = 0.5 mL)
        │
        ├─ LNP endocytosis: muscle cells, dermal fibroblasts, migratory DCs
        │
        ├─ Late endosome (pH ~5.5) → SM-102 protonation → membrane disruption
        │    mRNA released into cytoplasm
        │
        ├─ Ribosomes translate spike → membrane-anchored spike trimer displayed
        │
        ├─ MHC I loading of spike peptides → CD8⁺ CTL priming
        │
        └─ Secreted / shed spike trimers → lymph node B cells
             Germinal center → anti-RBD IgG1/IgG3 (neutralizing, dominant correlate)
             CD4⁺ Th1 help → B-cell class switching + CD8⁺ cytokine support
  1. N1-methylpseudouridine (m1Ψ): Every uridine replaced — evades TLR7/TLR8 and RIG-I innate RNA sensing; 10–100× increased translation efficiency; reduced reactogenicity vs. unmodified mRNA. Karikó & Weissman 2005 Nobel Prize-winning innovation.
  2. 2P prefusion stabilization: K986P + V987P lock the spike heptad repeat in its prefusion trimer conformation. Solved structure (PDB 6VSB) shows RBD in "up" state — exposing the ACE2 binding site epitope that is the dominant neutralizing target.
  3. SM-102 ionizable lipid: Proprietary to Moderna; near-neutral at physiological pH (avoids rapid clearance); protonates at endosomal pH to disrupt membrane and release mRNA into cytoplasm for ribosomal translation.
  4. In vitro transcription (IVT) manufacturing: mRNA is produced enzymatically from a linearized plasmid template using T7 RNA polymerase with m1Ψ-UTP. Rigorous purification removes dsRNA byproducts (highly inflammatory), residual DNA, and proteins. Drug product manufactured via microfluidic LNP encapsulation.
  5. No genomic integration: mRNA has no nuclear access, no reverse transcriptase in cytoplasm of somatic cells, and is degraded within days by RNases. No risk of permanent genetic modification.

Immunogenicity

Humoral Response

Anti-RBD IgG (predominantly IgG1/IgG3) is the dominant correlate of protection. Geometric mean titers after dose 2: ~10× convalescent serum benchmarks. Pseudovirus neutralization titers strongly predict risk of symptomatic COVID-19. Titers wane ~5-fold by 6 months; boosters restore peak levels.

CD4⁺ / CD8⁺ T-Cell Response

Th1-biased CD4&sup+ T cells (IFN-γ, IL-2, TNF-α). Spike-specific CD8&sup+ CTLs via MHC I loading. T-cell responses decline more slowly than humoral responses and correlate with protection against severe disease — important for variant-shifted strains where antibody neutralization is partially evaded.

Innate Activation

SM-102 LNP activates NLRP3 inflammasome and TLR4 at the injection site. m1Ψ modification attenuates TLR7/8 sensing of mRNA itself. Net result: moderate innate signal sufficient for DC maturation and adaptive priming without excessive inflammation — explaining why reactogenicity is greater at 100 µg than at lower doses.

Duration / Durability

Humoral: neutralizing titers wane with ~69-day half-life; ~5–10-fold fall by 6 months. Cellular: T-cell responses persist >12 months. Against Omicron (BA.1+): ~10–20× reduction in neutralizing titer motivating bivalent and updated boosters; T-cell cross-reactivity against conserved spike epitopes preserved, maintaining protection against severe disease.

Clinical Efficacy

TrialDesignnPrimary EndpointResult
Phase 1 NCT04283461 (Jackson 2020) Phase 1 dose-escalation, US adults 18–55 & older 45 (initial) + expansion Safety; dose selection (25/100/250 µg) 100 µg selected; all doses immunogenic; 250 µg excess reactogenicity
Phase 3 COVE NCT04470427 (Baden 2021, NEJM) Phase 3 RCT, 1:1 vaccine:placebo, US sites 30,420 Symptomatic COVID-19 ≥14d post-dose 2 94.1% efficacy (95% CI 89.3–96.8%); 100% severe disease prevention in primary analysis
COVE blinded-phase completion (El Sahly 2021) Extended COVE follow-up 30,420 Sustained efficacy through ~5 months 93.2% (95% CI 91.0–94.8%); durability confirmed
KidCOVE NCT04796896 Phase 2/3 pediatric bridging study ~13,000 Non-inferiority to adult immunogenicity Non-inferiority confirmed; dose-adjusted (50 µg, 25 µg) schedules for pediatric groups

Safety Profile

  • Very Common Injection-site pain, fatigue, headache, myalgia, chills — >50–85% of vaccinees after dose 2 (100 µg); onset 1–2 days; resolves within 2–3 days. More pronounced after dose 2 than dose 1, consistent with recall immune response. Grade 3 (limiting daily activity) in ~10–15% after dose 2 at 100 µg — higher frequency than BNT162b2, likely reflecting the 3.3× higher dose.
  • Common Fever (≥38°C) — ~15% after dose 2; <1% after dose 1. Erythema and swelling at injection site.
  • Rare / Serious Myocarditis / pericarditis — predominantly young adult males within 1–7 days of dose 2. Israeli surveillance: ~10–25 per 100,000 doses in highest-risk band (males 16–29). Slightly higher absolute rate than BNT162b2 at this age group, consistent with higher 100 µg dose. Most cases mild and self-limiting (full recovery expected). Mechanism: proposed molecular mimicry (spike epitopes cross-reactive with cardiac α-myosin), dysregulated innate-immune response to LNP/mRNA, or individual susceptibility loci — not resolved.
  • Very Rare Anaphylaxis — ~2–5 per million doses; related to PEG-lipid component; onset within 15–30 min; manageable with standard observation and epinephrine.
  • Not Established No VITT (unlike adenoviral vector vaccines); no evidence of genomic integration, infertility, or autoimmune signal in controlled studies.

Administration

ParameterDetails
Adult dose / schedule2 doses, 100 µg (0.5 mL) IM, 28 days apart; deltoid
Pediatric dosesAges 6–11: 50 µg (2 doses, 28d); ages 6 months–5 years: 25 µg (2 doses, 28d)
BoosterSingle 50 µg ≥5 months after primary; updated bivalent (BA.4/5) and XBB.1.5 monovalent formulations for annual updates
Storage−25°C to −15°C up to 9 months; 2–8°C up to 30 days (unpunctured); do not refreeze after thaw
ContraindicationsPrior anaphylaxis to mRNA-1273 or any component (PEG-DMG); severe allergy to polyethylene glycol; history of myocarditis/pericarditis after mRNA-1273 — discuss benefit-risk with cardiologist before booster

Connections

Immunizes vs. SARS-CoV-2 Elicits Immune System Elicits B Cell (anti-RBD IgG) Elicits T Helper Cell (Th1) Via Dendritic Cell Same Platform BNT162b2 Same Antigen AZD1222 Compare NVX-CoV2373

References